ISHITADR Stock Rating, Buy/Sell, Forecast | Indexgaze

Details

Name	Symbol	Sector
ISHITA DRUGS & INDUSTRIES LTD.	ISHITADR	Pharmaceuticals

Open

73.16

High

77.98

Low

73.16

Close

77.98

Volume

11

Exchange

bse

Time

14/08

Outlook

Score: 2.75
Rating: RISKY

Candlestick Pattern

Candle pattern of Ishita Drugs & Industries is Marubozu
Estimated Stoploss of Ishita Drugs & Industries is ₹ 73.16
Ishita Drugs & Industries has a Bullish pattern.
Formation of Marubozu candle pattern indicates Ishita Drugs & Industries has chances of Continuation of the current trend.

Trend

Ishita Drugs & Industries is in Sideways trend .
Price of Ishita Drugs & Industries is Up by 0.41 %.

Target

Buy @ 71.64
Sell @ 84.2

Volume

The trade volumes of Ishita Drugs & Industries have become Deficient
Though the volume trend for Ishita Drugs & Industries appears Bullish the participants seem to be Weak Buyers
The trade volume of Ishita Drugs & Industries is Down by 99.25 %

Valuation

The current market price of Ishita Drugs & Industries is Undervalued

Financials

Balance
The balance sheet of Ishita Drugs & Industries is: Balanced

Cashflow
Ishita Drugs & Industries has Poor cash flow because it is ₹ 0cr . It is Down by 100 %. (*Mar 2025) 42.86% i.e. ₹ 3cr spent in operating 0% in investing 57.14% i.e. ₹ 4cr earned in financing 0% in other
Ishita Drugs & Industries has Maintained cash flow because there is Surplus of ₹ 1cr . It is Up by 200 %. (*Mar 2024) 100% i.e. ₹ 2cr earned in operating 0% in investing 0% in financing 0% in other

Income
The income of Ishita Drugs & Industries is ₹ 5cr and Loss is : ₹ 0cr (Jun 2025) Ishita Drugs & Industries Losses increased by: 0 % and Income is Up by: 25 % (Jun 2025)
The income of Ishita Drugs & Industries is ₹ 4cr and Loss is : ₹ 0cr (Mar 2025) Ishita Drugs & Industries Losses increased by: 0 % and Income is Up by: 0 % (Mar 2025)
The income of Ishita Drugs & Industries is ₹ 4cr and Loss is : ₹ 0cr (Dec 2024) Ishita Drugs & Industries Losses increased by: 0 % and Income is Up by: 33.33 % (Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.